Evolus (NASDAQ:EOLS) Earns “Buy” Rating from BTIG Research

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock. BTIG Research’s target price would suggest a potential upside of 96.08% from the company’s previous close.

EOLS has been the subject of several other research reports. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Evolus currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Stock Down 1.8%

Evolus stock opened at $6.63 on Wednesday. The stock has a market capitalization of $436.62 million, a PE ratio of -9.90 and a beta of 1.34. Evolus has a twelve month low of $3.86 and a twelve month high of $10.20. The company has a 50 day moving average of $5.82 and a 200-day moving average of $5.55.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the business earned ($0.30) EPS. Equities analysts anticipate that Evolus will post -0.38 EPS for the current fiscal year.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 13,669 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the sale, the insider owned 604,700 shares of the company’s stock, valued at $2,872,325. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Evolus

A number of institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC raised its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Evolus during the fourth quarter worth $34,000. Wexford Capital LP bought a new stake in Evolus during the third quarter worth $37,000. Aquatic Capital Management LLC bought a new stake in Evolus during the third quarter worth $48,000. Finally, State of Wyoming bought a new stake in Evolus during the fourth quarter worth $63,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.